Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings
By Dr. Matthew Watson
Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber” or the "Company"), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that its Annual Meeting of Shareholders will be held at 1:00 pm EDT on Thursday, June 3, 2021 (the “Annual Meeting”). The Company has established April 12, 2021 as the record date for the Annual Meeting.
Related Post
- Number of voting rights as of March 31, 2021 - April 4th, 2021
- Multiple Former FDA Commissioners Voice Support for Reduced Nicotine Mandate; Proposed Legislation Would Be Game-Changing for 22nd Century - April 4th, 2021
- OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine - April 4th, 2021
- Tauriga Sciences Inc. Completes the Translations of Its 25mg Tauri-Gum Blister Pack Into the Following Languages: Mandarin Chinese, Japanese, Arabic,... - April 4th, 2021
- Autolus Therapeutics to Participate in Investor Conferences Through April - April 4th, 2021
- Syneos Health Schedules First Quarter 2021 Earnings Call for Thursday, April 29, 2021 - April 4th, 2021
- AgraFlora Announces Definitive Agreement to Sell its AAA Heidelberg Subsidiary - April 4th, 2021
- GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update - April 4th, 2021
- Neuronetics Announces Appointment of Robert Cascella to its Board of Directors - April 4th, 2021
- Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021 - April 4th, 2021
- Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 4th, 2021
- NKMax America Announces Corporate Name Change to NKGen Biotech - April 4th, 2021
- Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc. - April 4th, 2021
- Valneva - Déclaration d’actions et de droits de vote – Mars 2021 - April 4th, 2021
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 4th, 2021
- ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021 - April 4th, 2021
- DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors - April 4th, 2021
- Concerns about alcohol-based sanitisers are changing the way hospitals invest in protecting their staff - April 4th, 2021
- Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD - April 4th, 2021
- Gritstone Announces Promotions Within its Leadership Team - March 8th, 2021
- Spectral Medical Announces the Appointment of Chris Seto to CEO - March 8th, 2021
- Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity - March 8th, 2021
- Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease - March 8th, 2021
- Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference - March 8th, 2021
- Silo Wellness Kicks Off Second Oregon Psychedelic Wellness Retreat - March 8th, 2021
- TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors - March 8th, 2021
- Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic... - March 8th, 2021
- Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board - March 8th, 2021
- Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference - March 8th, 2021
- Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021 - March 8th, 2021
- XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection - March 8th, 2021
- AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test - March 8th, 2021
- Fierce Medtech Names Canary Medical a “Fierce 15” Company for 2020 - March 8th, 2021
- INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 - March 8th, 2021
- AgraFlora Appoints Elise Coppens as New CEO and Director to Implement the Next Phase of its Corporate Strategy - March 8th, 2021
- AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study - March 8th, 2021
- Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March - March 8th, 2021
- Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s... - March 8th, 2021
- Global WholeHealth Partners Corp (OTC:GWHP) to Announce that Global is Now Offering the AstraZeneca Vaccines as Mentioned in 8K Filing on 03/02/21 - March 8th, 2021
- Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference - February 19th, 2021
- Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - February 19th, 2021
- Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference - February 19th, 2021
- Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol... - February 19th, 2021
- Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021 - February 19th, 2021
- BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report® - February 19th, 2021
- BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i... - February 19th, 2021
- Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA - February 19th, 2021
- Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates - February 19th, 2021
- Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform - February 19th, 2021
- Assembly Bio Announces Upcoming Investor Events - February 19th, 2021
- RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 19th, 2021
- Intercept to Present at Upcoming Investor Conferences - February 19th, 2021
- CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology - February 19th, 2021
- Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan - February 19th, 2021
- Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million - February 19th, 2021
- Information expressed in the public domain by the Repharm Group is deceptive and contradictory - February 19th, 2021
- Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on... - February 19th, 2021
- Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021 - February 19th, 2021
- Ayala Pharmaceuticals Announces $25 Million Strategic Financing - February 19th, 2021
- Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update - February 17th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - February 17th, 2021
- Lumos Pharma Announces Changes to its Board of Directors - February 17th, 2021
- Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference - February 17th, 2021
- Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels - February 17th, 2021
- Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - February 17th, 2021
- Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 - February 17th, 2021
- MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021 - February 17th, 2021
- Aleafia Health Announces $15 Million Bought Deal Offering of Units - February 17th, 2021
- Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side - February 17th, 2021
- ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome - February 17th, 2021
- Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results - February 17th, 2021
- Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference - February 17th, 2021
- ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference - February 17th, 2021
- Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million - February 17th, 2021
- Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities... - February 17th, 2021
- Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease - February 17th, 2021
- Vistin Pharma ASA: Invitation to Q4 2020 conference call - February 14th, 2021
Global News Feed
Comments Off on Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings |
April 4th, 2021
This author published 3752 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research